Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
PMV Pharmaceuticals, Inc
Kivu Bioscience Inc.
NeoImmuneTech
BeOne Medicines
Neonc Technologies, Inc.
Eli Lilly and Company
Radiopharm Theranostics, Ltd
NiKang Therapeutics, Inc.
MacroGenics
AstraZeneca
SystImmune Inc.
SN BioScience
Radiopharm Theranostics, Ltd
ImmunityBio, Inc.
GV20 Therapeutics
DualityBio Inc.
National Institutes of Health Clinical Center (CC)
Incyte Corporation
M.D. Anderson Cancer Center
NiKang Therapeutics, Inc.
Merck Sharp & Dohme LLC
Pfizer
Incyte Corporation
University of Virginia
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
Marengo Therapeutics, Inc.
Klus Pharma Inc.
Theratechnologies
National Institutes of Health Clinical Center (CC)
Stanford University
Cybrexa Therapeutics
Sotio Biotech Inc.
Cyteir Therapeutics, Inc.
Carisma Therapeutics Inc
Tasly Biopharmaceuticals Co., Ltd.
Sellas Life Sciences Group
Vincerx Pharma, Inc.
AstraZeneca
Salubris Biotherapeutics Inc
Merck Sharp & Dohme LLC
Xencor, Inc.
Advaxis, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
Exelixis
Memorial Sloan Kettering Cancer Center
Evopoint Biosciences Inc.
Zhejiang University